Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017:2017:9264904.
doi: 10.1155/2017/9264904. Epub 2017 Jun 11.

Peritransplant Soluble CD30 as a Risk Factor for Slow Kidney Allograft Function, Early Acute Rejection, Worse Long-Term Allograft Function, and Patients' Survival

Andriy V Trailin  1 , Tetyana I Ostapenko  2 , Tamara N Nykonenko  3 , Svitlana N Nesterenko  4 , Olexandr S Nykonenko  2
Affiliations

Peritransplant Soluble CD30 as a Risk Factor for Slow Kidney Allograft Function, Early Acute Rejection, Worse Long-Term Allograft Function, and Patients' Survival

Andriy V Trailin et al. Dis Markers. 2017.

Abstract

Background: We aimed to determine whether serum soluble CD30 (sCD30) could identify recipients at high risk for unfavorable early and late kidney transplant outcomes.

Methods: Serum sCD30 was measured on the day of kidney transplantation and on the 4th day posttransplant. We assessed the value of these measurements in predicting delayed graft function, slow graft function (SGF), acute rejection (AR), pyelonephritis, decline of allograft function after 6 months, and graft and patient survival during 5 years of follow-up in 45 recipients.

Results: We found the association between low pretransplant serum levels of sCD30 and SGF. The absence of significant decrease of sCD30 on the 4th day posttransplant was characteristic for SGF, early AR (the 8th day-6 months), late AR (>6 months), and early pyelonephritis (the 8th day-2 months). Lower pretransplant and posttransplant sCD30 predicted worse allograft function at 6 months and 2 years, respectively. Higher pretransplant sCD30 was associated with higher frequency of early AR, and worse patients' survival, but only in the recipients of deceased-donor graft. Pretransplant sCD30 also allowed to differentiate patients with early pyelonephritis and early AR.

Conclusions: Peritransplant sCD30 is useful in identifying patients at risk for unfavorable early and late transplant outcomes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
ROC curve for pretransplant serum sCD30 to predict SGF. AUC (95% confidence intervals) is 0.781 (0.613–0.948), P = 0.023. ROC: receiver-operating characteristic; AUC: area under the curve; sCD30: soluble CD30; SGF: slow graft function.
Figure 2
Figure 2
ROC curve for pretransplant serum sCD30 to predict early AR after cadaver kidney transplantation. AUC (95% confidence intervals) is 0.829 (0.613–1.000), P = 0.033. ROC: receiver-operating characteristic; AUC: area under the curve; sCD30: soluble CD30; AR: acute rejection.
Figure 3
Figure 3
ROC curve for pretransplant serum sCD30 to discriminate between early AR and pyelonephritis. AUC (95% confidence intervals) is 0.938 (0.762–1.000), P = 0.043. ROC: receiver-operating characteristic; AUC: area under the curve; sCD30: soluble CD30; AR: acute rejection.
Figure 4
Figure 4
Impact of pretransplant sCD30 on patient survival (a) and death-censored graft survival (b) after cadaver kidney transplantation (Kaplan–Meier estimates). P values are calculated with the log-rank test. sCD30: soluble CD30.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Saran R., Li Y., Robinson B., et al. US renal data system 2014 annual data report: epidemiology of kidney disease in the United States. American Journal of Kidney Diseases. 2014;66(1) supplement 1:S1–S306. doi: 10.1053/j.ajkd.2015.05.001. - DOI - PMC - PubMed
    1. Aguiar B., Santos Amorim T., Romãozinho C., et al. Malignancy in kidney transplantation: a 25-year single-center experience in Portugal. Transplantation Proceedings. 2015;47(4):976–980. doi: 10.1016/j.transproceed.2015.03.039. - DOI - PubMed
    1. Israni A. K., Snyder J. J., Skeans M. A., et al. PORT investigators. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) study. American Journal of Transplantation. 2010;10(2):338–353. doi: 10.1111/j.1600-6143.2009.02949.x. - DOI - PubMed
    1. Wang D., Wu W. Z., Chen J. H., et al. Pre-transplant soluble CD30 level as a predictor of not only acute rejection and graft loss but pneumonia in renal transplant recipients. Transplant Immunology. 2010;22(3-4):115–120. doi: 10.1016/j.trim.2009.12.004. - DOI - PubMed
    1. Kim M. S., Kim H. J., Kim S. I., et al. Pretransplant soluble CD30 level has limited effect on acute rejection, but affects graft function in living donor kidney transplantation. Transplantation. 2006;82(12):1602–1605. doi: 10.1097/01.tp.0000248779.17754.5e. - DOI - PubMed

MeSH terms